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Abstract
Background: The screening of ROS proto-oncogene 1, receptor tyrosine kinase(ROS1) fusion rearrangement might
be potentially beneficial for an effective therapy against non-small cell lung cancer (NSCLC). However, the three
main ROS1 rearrangement detection methods have limitations, and no routine protocol for the detection of ROS1
rearrangement in NSCLC is available. In this study, our aims were to compare immunohistochemistry (IHC),
fluorescent in situ hybridization (FISH) and quantitative real-time polymerase chain reaction (qRT-PCR) in their ability
to detect ROS1 rearrangement in NSCLC, and discuss the clinical characteristics and histopathology of the patients
with ROS1 rearrangement. Moreover, the effects of tyrosine kinase inhibitors (TKIs) therapy on the patients with
ROS1 rearrangement and advanced stage disease (III b–IV) were investigated.
Methods: Patients with a previously diagnosed NSCLC were recruited in this study from November 2013 to
October 2015. IHC was performed using the D4D6 monoclonal antibody (mAb) in an automatic IHC instrument,
while FISH and qRT-PCR were carried out to confirm the IHC results. FISH and qRT-PCR positive cases underwent
direct sequencing. After detection, patients with advanced ROS1 rearranged NSCLC had received TKI therapy.
Results: Two hundred and thirty-eight patients were included in this study. ROS1 rearrangement was detected in
10 patients. The concordant rate of FISH and qRT-PCR results was 100 %, while in the FISH and IHC results high
congruence was present when IHC showed a diffusely (≥60 % tumor cells) 2–3+ cytoplasmic reactivity pattern.
Patients harboring ROS1 rearrangement were mostly young (8/10), females (7/10) and non-smokers (7/10) with
adenocarcinoma (10/10) and acinar pattern. Most of their tumor were in intermediate grade (6/8). Among these 10
patients, three of them in stage IV with ROS1 rearrangement gained benefits from ROS1 TKI therapy.
Conclusions: IHC, FISH and qRT-PCR can reliably detect ROS1 rearrangement in NSCLC, while IHC can be used as a
preliminary screening tool. These results supported the efficacy of ROS1 TKI therapy in treating advanced NSCLC
patients with ROS1 rearrangement.
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Background
Mutations in receptor tyrosine kinases (RTKs) genes
have been identified as the main cause of many
carcinomas development, since they can lead to pro-
liferation and transformation of cancer cells [1]. In re-
cent years, ROS proto-oncogene 1, receptor tyrosine
kinase (ROS1), a gene located on 6q22, which transcripts
the protein that belongs to the subfamily of tyrosine
kinase insulin receptor, has been recognized as a driver
of non-small cell lung cancer (NSCLC) [2] since it can
fuse with other genes (e.g. CD74, SLC34A2, FIG, TPM3,
SDC4, EZR, LRIG3, CCDC6, and KDELR2 [3, 4]) and
consequently activate the downstream growth and
survival signaling pathways [3–7]. In most cases, ROS1
fusion rearrangement is exclusive to other RTK aber-
rance, such as the anaplastic lymphoma receptor
tyrosine kinase (ALK) rearrangement, epidermal growth
factor receptor (EGFR) mutations and Kirsten rat
sarcoma viral oncogene homolog (KRAS) mutations [4].
Moreover, because of the homology between the ROS1
and ALK proteins [8, 9], patients with ROS1 re-
arrangement are sensitive to ALK tyrosine kinase inhi-
bitors (TKIs). Therefore, despite the incidence of ROS1
rearrangements in NSCLC is low (1–2 %) [4, 10],
screening ROS1 rearrangement could be potentially
beneficial for NSCLC patients.
In the present work, fluorescent in situ hybridization
(FISH), quantitative real-time polymerase chain reaction
(qRT-PCR) and immunohistochemistry (IHC) have been
used for ROS1 arrangement detection. All of these
methods have advantages and limitations. FISH analysis
can reveal the genes rearrangement status, but the
procedure is inconvenient [11, 12], and it is not suitable
for biopsies with insufficient numbers of tumor cells.
qRT-PCR analysis can reveal fusion rearrangements by
using specific primers and it has a high sensitivity.
However, qRT-PCR cannot detect specimens with
unknown fusion types [11, 12]. IHC is feasible in large
scale screening, and the D4D6 rabbit monoclonal anti-
body (mAb) has been identified as effective and specific
mAb for ROS1 rearrangement protein detection by
several studies [3, 8, 11]. In addition, the costs to per-
form IHC are less compared with qRT-PCR or FISH.
However, there is not an accurate cutoff value to define
positive ROS1 protein expression using IHC, thus re-
presenting a limitation on using this method [11–14].
Therefore, the aim of this study was to compare these
three analytical methods in their ability to detect ROS1
rearrangement in NSCLC, trying to set up a cutoff value
for ROS1 IHC analysis. In addition, we investigated the
efficacy of TKI therapy in treating advanced NSCLC
patients with ROS1 rearrangement. The characteristics




Patients admitted to the First Affiliated Hospital of
Guangzhou Medical University were screened and
recruited for this study from November 2013 to October
2015. Patients were selected upon (1) a previous identifi-
cation of NSCLC with (2) a confirmed diagnosis by IHC
of p63, CK5/6, NapsinA and TTF-1 protein expression
[15]. A cohort of 238 NSCLC patients was included.
Afterwards, all slides from the chosen cases were
independently analyzed by two pathologists (X Gu & JY
Wu) blinded to history and prior diagnoses. The histo-
pathological classification was performed according to the
2015 WHO classification of lung tumors [15] and the
International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society
(IASLC/ATS/ERS) multidisciplinary classification [16].
Appropriate specimens with sufficient tissue (>100 tumor
cells) were included.
After recruitment, the clinical information, including
age, gender, smoking history, and tumor node metastasis
(TNM 7th) staging were collected. In adenocarcinoma
cases, the histological grading was performed by analyz-
ing the single most predominant pattern in a case [15].
According to 2015 WHO histological grading of adeno-
carcinoma, the grading was divided into low, intermediate
and high. Another grading score system that combined
the most two predominant pattern in a case was also been
used, which was worked out by Sica et al. [17]. The results
of other genetic markers testing were also collected, such
as ALK, EGFR and KRAS. Ventana IHC with D5F3 mAb
and FISH with break-apart probe were used in ALK
rearrangement detection. Amplification refractory muta-
tion system polymerase chain reaction (ARMS-PCR) was
used to detect EGFR and KRAS gene mutation. This study
was approved by the Ethic Review Committee of the First
Affiliated Hospital of Guangzhou Medical University.
Immunohistochemistry (IHC)
All the specimens were formalin-fixed and paraffin
embedded (FFPE). ROS1 IHC was performed on 4 μm
slides and completed on a fully automated IHC instru-
ment (BenchMark XT, Roche, Switzerland). D4D6 rabbit
mAb (Cell Signaling Technology, Danvers, MA) diluted
in 1:200 was used as primary antibody. Detection was
using UltraView Universal DAB detection Kit (Roche,
Switzerland). IHC was scored using the following score
scheme: 0, no staining of tumor cells; 1+, tumor cells
with faint cytoplasmic reactivity without any background
staining; 2+, tumor cells with moderate cytoplasmic
reactivity; and 3+, tumor cells with strong granular
cytoplasmic reactivity [11]. When several intensity levels
present in a case, it was scored according to the intensity
of major tumor cells. The extent of IHC staining was
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also analyzed by estimating the staining percentage of
tumor cells [8]. Moreover, H-score method was used and
calculated using the following equation: H-score = ∑[in-
tensity (0, 1, 2, 3) × extent of each staining intensity(%)],
with a scoring range from 0 to 300 [14]. Previous lung
specimens with ROS1 rearrangements confirmed by FISH
and a 3+ staining score, have been used as positive con-
trol. IHC was analyzed independently by two pathologists
(X Gu & JY Wu), and disagreements were discussed after
the analysis. A third pathologist (XG Fu) was invited as
the reviewer when an agreement could not be reached.
The above results were blinded for the qRT-PCR results.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from FFPE tissue sections (6 μm
slides) using the FFPE RNA Kit (Amoy Diagnostics Co.,
Ltd, Xiamen, China). RNA concentration was measured
using a spectrophotometer (Nanodrop 2000c, Thermo-
Scientific, Wilmington, US) and reverse transcription was
performed to generate complementary DNA (cDNA). The
cDNA was used for multiple RT-PCRs that were carried
out in an Mx3000p real-time PCR system (Agilent Tech-
nologies, California, US) using the ROS1 Gene Fusion De-
tection Kit (Amoy Diagnostics Co., Ltd, Xiamen, China).
The positive and negative reference samples were also
used. The PCR procedure was the following: One cycle at
95 °C for 5 min; 15 denaturation cycles at 95 °C for 25 s,
annealing at 64 °C for 20 s and elongation at 72 °C for
20 s; 31 cycles at 93 °C for 25 s, 60 °C for 35 s (data collec-
tion) and 72 °C for 20 s. The quantification is determined
by the fusion fluorescence signals and the assay with a Ct
value < 30 cycles was considered as positive. These results
were blinded for the IHC and FISH results.
Tissue microarray (TMA) and fluorescent in situ
hybridization (FISH)
IHC positive staining areas were evaluated and selected
from the slides by a pathologist (JY Wu) to avoid tumor
heterogeneity and the tissue microarray (TMA) was per-
formed from the FFPE samples. Two areas of 2 mm
diameter were removed from each sample block using a
stainless steel stylet (Xinsen, Jieli Biomedicine Co., Ltd,
Guangzhou, China). Serial 4 μm TMAs sections were
used for FISH detection using 6q22 ROS1 Break Apart
FISH Probe RUO Kit (Abbott Molecular Inc, IL, USA).
The protocol and interpretation of FISH were the
following: TMA slides were submerged in xylene and
decreasing gradient of ethanol for deparaffinization and
hydration, respectively. Next, they were subjected to a
heat-treatment in boiled water (100 °C, 30 min) and
digestion using proteinase K (37 °C, 5 min). They were
washed in 2 × SSC solution and dehydrated by increasing
gradient of ethanol (70 %, 85 % and 100 %) for 3–5 min.
After air drying, the probe was added to the target
specimens, and coverslips were placed. The slides were
placed in the hybridization machine (ThermoBrite,
Abbott Molecular Inc, IL, US) and hybridization was
performed as follows: denaturation at 75 °C for 8 min
and hybridization at 42 °C for 16 h. Next, the slides were
washed in 2 × SSC and NP40 solution at 42 °C for 5 min
and immersed in 70 % ethanol for 5 min. DAPI 15 μl
was applied to counterstain. Analysis was performed in
the dark using the fluorescence microscopy (Nikon 80i,
Japan). The data analysis was the following: >15 % tumor
cells showing split signals (“red” and “green” split
signals) or isolated 3′ signals (single “green” signals)
belonged to the ROS1 fusion rearrangement. These
results were blinded for the qRT-PCR results.
Direct sequencing
The cDNA of FISH and qRT-PCR positive cases were
sent to Amoy Diagnostics Co., Ltd for direct sequencing.
The results of the sequencing were compared using the
Basic Local Alignment Search Tool (BLAST).
Follow-up visits
After ROS1 rearrangement detection using IHC, FISH
and qRT-PCR, the patients harboring ROS1 rearrangement
in advanced stages (III b–IV) of disease were selected for
TKI therapy. In order to track the efficacy of the therapy,
information such as patient’s syndromes, vital signs and CT
images were collected every two months. The efficacy was
evaluated using RECIST guideline 1.1 [18]. The materials of
patients were authorized by the recruited patients and (or)
their family members.
Statistical analysis
Pearson’s χ2 and Fisher’s exact test were used to assess
the relationship between ROS1 rearrangement, clinical
characteristics and clinicopathological patterns. The Kappa
value was calculated to assess the concordant rate of FISH
and IHC in detecting ROS1 rearrangement. The analyses
were carried out using the Statistical Package for the Social
Sciences (SPSS) version 13.0 (SPSS, Inc., Chicago, IL, US),
and P values less than 0.05 were considered statistically
significant.
Result
Characteristics of the recruited cases
Two hundred and thirty-eight cases were recruited, of
which 215 were surgical resection cases and 23 were
needle biopsy cases. The clinical characteristics and
histopathology of the patients are shown in Table 1. The
median age was 61 years old (range from 27 to 85 years
old), and 107 were females and 131 were males. Most of
the included cases were in the early stages (114/238,
47.9 %) of the disease, while 48 (48/238, 20.2 %) cases
were in the advanced stages (III b–IV). Total 181
Wu et al. BMC Cancer  (2016) 16:599 Page 3 of 12
Table 1 Characteristic of included cases
Characteristic Total Surgery resection Biopsy ROS1 rearrangement ROS1 non–rearrangement P.
No. 238 215 23 10 228
Age 0.114a
>61 109 101 8 2 107
≤61 129 114 15 8 121
Gender 0.118a
Male 131 118 13 3 128
Female 107 97 10 7 100
Smoking history 0.792a
Smoker 51 48 3 3 48
Non–smoker 158 140 18 6 152
Previous smoker 29 27 2 1 28
Histopathology 1.000a
ADC 216 (8)b 195 (6)b 21 (2)b 10 206 (8)b
SCC 11 9 2 0 11
ASC 2 2 – 0 2




Lepidic 17 17 – 2 15
Acinar 105 105 – 4 101
Papillary 33 33 – 3 30
Micropapillary 16 16 – 2 14
Solid 20 20 – 0 20
Invasive mucinous
adenocarcinoma
8 8 – 1 7
Fetal 1 1 0 1
TMN staged 0.175a
I 114 114 0 6 108
II 30 29 1 1 29
III 55(IIIb:10) 53 2 0 55
IV 38 18 20 3 35
Sica gradinge 0.871a












Table 1 Characteristic of included cases (Continued)
Score 3 48 48 - 3 45
Score 4 48 48 - 1 47
Score 5 69 69 - 4 65
Score 6 10 10 - 0 10
WHO gradinge 0.597a
Low grade 17 17 - 1 16
Intermediate grade 126 126 - 5 121
High grade 38 38 - 2 36
Another gene status –
ALK 228 (12)f 206 (11)f 22 (1)f 0 228
EGFR 163 (87)f 141 (78)f 22 (9)f 0 163
exon 19 deletion 37 33 4 0 37
L858R 48g 44g 4 0 48
L861Q 1 1 0 0 1
exon 20 S768I 2g 1g 1 0 2
KRAS 153 (13)f 136 (11)f 17 (2)f 0 153
Gly12Asp 3 3 0 0 3
Gly12Cys 4 4 0 0 4
Gly12Val 4 4 0 0 4
Gly12Ala 1 0 1 0 1
Gly12Ser 1 0 1 0 1
Abbreviations: ADC Adenocarcinoma, SCC Squamous cell carcinoma, ASC Adenosquamous carcinoma, LCLC Large–cell lung carcinoma, ALK anaplastic lymphoma receptor tyrosine kinase, EGFR epidermal growth factor
receptor, KRAS Kirsten rat sarcoma viral oncogene homolog
aFisher exact test
bMetastasis cases
cTotal 190 resected adenocarcinoma with 200 predominant patterns were discussed. Some cases were including more than one predominant patterns
dA case was diagnosed as stage 0
eTotal 181 resected adenocarcinoma have been analyzed, excluding variant subtypes
fThe cases with ALK rearrangement, EGFR mutation or KRAS mutation












resected adenocarcinoma cases were performed histo-
logical grading, they mostly obtained score 5 in Sica staging
(69/181, 38.1 %) and classified as intermediate grade in the
WHO grading (126/181, 69.6 %). Details of the grading
were showed in a supplementary table [see Additional file
1: Table S1]. However, there was no statistical difference
between ROS1 rearrangement and non-rearrangement
cases in clinical characteristics. Two hundred and twenty-
eight patients underwent ALK rearrangement detection,
163 and 153 patients underwent EGFR and KRAS muta-
tion detection, respectively. Among these cases, 12 cases
(12/228, 5.3 %) were harboring ALK rearrangement, 87
cases (87/163, 53.4 %) and 13 cases (13/153, 8.50 %) were
harboring EGFR and KRAS mutation, respectively.
Comparison of IHC, FISH and qRT-PCR in ROS1
rearrangement detection
All the recruited patients underwent FISH and IHC
detection of ROS1 rearrangement, and qRT-PCR ana-
lysis was applied in 159 cases. A total of 10 cases were
confirmed as ROS1 rearrangement positive by FISH (10/
238, 4.2 %; Table 2). Six of them underwent qRT-PCR
detection, which confirmed the presence of ROS1 re-
arrangement. All qRT-PCR negative cases were also
confirmed as ROS1 rearrangement negative by FISH.
Forty-two cases showed cytoplasmic reactivity by IHC.
Nevertheless, only ten cases with diffuse 2–3+ tumor
cytoplasmic reactivity were confirmed as ROS1 rearrange-
ment when FISH was set as the standard method. The
staining was distributed in more than 60 % tumor cells
(Table 2; Fig. 1j & n). A setting of 2+ in intensity, 60 % in
extent, and an H-score of 150 as the cutoff value repre-
sented the optimal IHC settings to reach the highest sensi-
tivity and specificity on ROS1 rearrangement detection
(Table 3) [19]. A concordance between FISH and IHC was
found when IHC showed moderate to strong cytoplasmic
reactivity (2–3+) with diffuse (≥60 %) distribution or H-
score≥ 150. (P < 0.01, Kappa value > 0.6; Table 4).
Characteristics of the positive cases
Ten cases were identified as positive for ROS1 re-
arrangement. Most of the positive cases were female
(Female: Male = 7:3) and non-smokers (7/10) with youn-
ger age (<61 year-old, 8/10). All the cases with ROS1
rearrangement were diagnosed as adenocarcinoma
(Tables 1 and 2), and acinar pattern was the most
predominant observed pattern. Eight cases could be
performed histological grading, five of them got score 5 in
Sica grading and 6 of them were classified as intermediate
grade by WHO grading. Six of the rearrangement cases
had been analyzed using direct sequencing (Table 2), re-
vealing that CD74-E6 was the most common mutation type
(3/6, 50 %). The images of direct sequencing are shown in
an additional figure [see Additional file 2: Figure S1]. Most
cases showed cytoplasmic and focal granular reactivity (7/
10, 70 %; Table 2) [see Additional file 3: Figure S2, c & d].
No correlation was found between histopathology predom-
inant patterns and IHC staining patterns (P = 0.645, Fisher
exact test). All cases with ROS1 rearrangement were not
carrying ALK, EGFR and KRAS gene aberrance.
The remaining 32 cases presented weak or focal IHC
staining confirmed as ROS1 gene non-rearrangement
or non-amplification by FISH. The staining patterns
are shown in an additional figure [see Additional file 3:
Figure S2]. All of them were diagnosed as adenocarcin-
oma. A case with an H-score of 90 and 2+ of intensity
had been confirmed as ROS1 non-rearrangement by
FISH. Its IHC staining was focal and represented ap-
proximately the 40 % of the tumor cells (Fig. 1f ).
Twenty-three of these cases underwent EGFR muta-
tion detection, and 17 of them were confirmed as
EGFR mutation (8 with exon 19 deletion and 9 with
exon 21 L858R mutation). Thirty of them underwent
ALK rearrangement detection, and two cases were
confirmed as ALK rearrangement.
Information related to the follow-up studies
Three patients (case 3, 6 and 7) (Table 2) belonging to the
ten ROS1 rearrangement cases at the stage IV of their dis-
ease, received the therapy of crizotinib, a TKI approved by
the Food and Drug Administration (FDA). The informa-
tion related to these three patients is shown in Table 5.
Details of these patients can be found in a supplementary
material [see Additional file 4: Figure S3 (a-c)].
Discussion
In the present study, three methods for ROS1 rearrange-
ment detection have been compared. The results showed
that D4D6 mAb IHC can be a reliable and feasible
method for preliminary screening of ROS1 rearrange-
ment in NSCLC, since it showed a high sensitivity and
specificity. Nevertheless, the IHC cutoff value should be
set at 2–3+ cytoplasmic reactivity with diffuse (≥60 % of
the tumor cells) distribution or an H-score ≥150, which
was similar to the conclusion of Yoshida’s study [14].
When we analyzed the pattern of IHC staining, we real-
ized that the distribution of the cytoplasmic reactivity is
one of the most important aspects in ROS1 IHC analysis.
Indeed, a 2+ cytoplasmic reactivity intensity could be a
false positive when the staining shows a focal distribution.
In order to verify and confirm the weak or focal cyto-
plasmic reactivity, FISH and qRT-PCR should be used as
secondary confirmation. In our study, the concordant
rate between qRT-PCR and FISH was 100 %, indicating
that qRT-PCR could be a reliable detection method for
ROS1 rearrangement. In addition, some studies have
indicated that FISH cannot clearly reveal the rearrange-
ments on the same chromosome, such as GOPC (FIG)-
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Table 2 The characteristics of patients with ROS1 rearrangement
Cases No. Smokinga Staging/Gradingb IHC resultc H-score FISH result Direct sequencing Histopathology
predominant pattern
Staining Pattern Another gene aberranced
1 N II B/
Score 5/Grade 2
3+/90 % 260 Fusion positive SLC34A2-E4; ROS1-E32/S
LC34A2-E4; ROS1-E34
Acinar Cytoplasmic; membrane ALK\EGFR\KRAS(−)
2 N I A/Score 3/
Grade 2/
2+/65 % 150 Fusion positive CD74-E6; ROS1-E34 Acinar Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
3 P IV/−/− 2+/70 % 160 Fusion positive CD74-E6; ROS1-E34 Invasive mucinous
adenocarcinoma
Mucinous staining ALK\EGFR\KRAS(−)
4 N I A/Score 5/
Grade 2
2+/90 % 200 Fusion positive TPM3-E8; ROS1-E35 Papillary and acinar Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
5 N I A/Socre 5/
Grade 3
2+/90 % 200 Fusion positive SLC34A2-E14del; ROS1-E32/
SLC34A2-E14del; ROS1-E34
Papillary and micropapillary Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
6 N IV/ Socre4/
Grade 2
3+/85 % 250 Fusion positive CD74-E6; ROS-E34 Acinar Cytoplasmic; granular ALK\EGFR\KRAS(−)
7e N IV/−/− 2+/70 % 160 Fusion positive – Invasive adenocarcinoma
with acinar pattern
Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
8 S I A/Score 5/
Grade 3
3+/90 % 250 Fusion positive – Papillary and micropapillary Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
9 S I B/Socre 3/
Grade 2
2+/80 % 180 Fusion positive – Acinar and lepidic Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
10 N I B/Score 3/
Grade 1
2+/80 % 180 Fusion positive – Lepidic Cytoplasmic; focal granular ALK\EGFR\KRAS(−)
aN, non-smoker; S, smoker; P, previous smoker
bTNM staging, SICA grading and WHO grading
cIHC results were containing intensity and extent scores
dALK rearrangement, EGFR and KRAS mutation have been also investigated at the sme time. The cases harboring ROS1 rearrangement were exclusive to ALK rearrangement, EGFR and KRAS mutation












ROS1 and EZR-ROS1 [4, 13]. Therefore, qRT-PCR can
be used as a second confirmatory test for revealing these
rearrangements. In contrast, the cases that resulted
negative after qRT-PCR analysis should be confirmed by
FISH since the primers of qRT-PCR do not contain
unknown fusion partners [12]. Finally, we designed a
protocol for the detection of ROS1 rearrangement
shown in Fig. 2 that encompassed these considerations.
The clinical characteristics and pathological pattern of
patients with ROS1 rearrangements were also discussed
in this study. Even though there were no significant
difference between ROS1 rearrangement and non-
rearrangement patients, the cases with ROS1 rearrange-
ment were mostly females at a younger ages and non-
smokers with adenocarcinoma, which was similar to the
results of some previous studies [20–22]. Most cases
were classified as intermediate grade by WHO grading,
however, five of them obtained score 5 in Sica grading,
which indicated these cases containing high grade
patterns as well. This result revealed that ROS1
rearrangement might become a prognosis biomarker of
NSCLC. However, this finding should be confirmed in
future study. Most ROS1 rearrangement cases presented
cytoplasmic and focal granular staining pattern in the
IHC staining, which was similar to the finding of some
previous studies [14, 23]. However, the correlation
between histopathology patterns and IHC staining
patterns, as well as the correlation between fusion types
and IHC reactivity patterns were not found due to the
lack of ROS1 rearrangement cases. In addition, all the
ROS1 rearrangement cases in our study were not carry-
ing ALK rearrangement, as well as EGFR and KRAS
mutations. Even though the overlapping phenomenon
has been reported in some rare cases [8, 22], the result
Fig. 1 Comparison of IHC, FISH and qRT-PCR in ROS1 rearrangement and non-rearrangement cases (a–d). The H&E staining, IHC, FISH and
qRT-PCR results of a non-rearrangement case. a The case presented acinar and papillary patterns in H&E staining (200×); b IHC showed no
staining in tumor cells (200×); c, d it was confirmed by FISH and qRT-PCR as non-rearrangement, respectively; e–h A case with weak and focal
ROS1 IHC staining. e The case presented acinar pattern in H&E staining (200×); f IHC showed weak to moderate focally staining in about 40 %
tumor cells (200×); g, h it was also confirmed as non-rearrangement by FISH and qRT-PCR, respectively; i–l A case with diffusely moderate IHC
staining. i The case presented papillary and micropapillary patterns in H&E staining (200×); j IHC showed moderate staining with cytoplasmic and
focal granular patterns in about 80 % tumor cells (200×); k and l it was proved as ROS1-rearrangement by FISH and qRT-PCR, respectively; m-p A
case with diffusely strong IHC staining. m The case presented papillary and micropapillary pattern in H&E staining (200×); n IHC showed diffusely
strong staining with cytoplasmic, membrane and granular patterns in about 90 % tumor cells (200×); o, p it was also proved as ROS1
rearrangement by FISH and qRT-PCR
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in our study indicated that general oncogene mutations
not necessarily overlap in the same patient [4, 21].
Thirty-two cases with IHC weak or focal reactivity had
been confirmed as ROS1 non-rearrangement. Although
we had set the tissue with IHC strong reactivity as the
positive control to avoid misunderstanding with the back-
ground staining, and chosen two areas with IHC reactivity
in each FFPE block to decrease heterogeneity in establish-
ing TMAs, these weak or focal staining might still be
related to background staining or tissue heterogeneity.
Nevertheless, among these cases, 17 were carrying EGFR
mutation and 2 were harboring ALK rearrangement. To
explain this phenomenon, Li et al. [24] investigated the
expression of ROS1 mRNA in NSCLC, and found that the
level of ROS1 mRNA increased either in ALK rearrange-
ments or EGFR mutation specimens. However, the
specific mechanism was unknown. We speculated that the
weak or focal staining of ROS1 IHC may result from
cross-talk mechanism of EGFR, ALK and ROS1 pathways,
which is similar to the mechanism of EGFR mutation in
NSCLC with MET proto-oncogene protein expression
[25, 26]. However, EGFR mutation and ALK rearrange-
ment detection was not possible on the remaining 9 and 2
cases, respectively. Thus, we cannot conclude that there
was a correlation between weak or focal staining of ROS1
IHC and other genes aberrance.
After all the analyses, three patients with stage IV and
ROS1 rearrangement underwent crizotinib therapy. All of
them showed a partial response (PR) after 2 to 8 weeks,
which was similar to some previous studies [8, 24]. In
addition, even two patients had received chemotherapy
before TKI therapy (patient 3 & 6), both of them had the
same response to crizotinib as the other patient (patient
7), which indicated that crizotinib is also sensitive to the
patients after chemotherapy. These three patients under-
went crizotinib therapy for at least 11 months, reaching
an average PR after 13.7 months. Since our patients were
under a follow-up schedule, we could not estimate the
progression-free survival (PFS). A large-scale study
showed that the PFS of patients under crizotinib carrying
ROS1 rearrangement was longer than the patients carry-
ing ALK rearrangement undergoing the same therapy,
suggesting the possible mechanism that imply crizotinib
binding more tightly to ROS1 than to ALK [8].
Tiredness was the most common symptom during the
therapy, and a patient (patient 6) also suffered from both
lower limbs edema without cardiac dysfunction, which is
one of the most common side effects observed in a
previous study [8]. However, the correlation between
TKI response and fusion partners had not been
discussed because of the reduced ROS1 rearrangement
cases to draw relevant conclusions. Because the FDA has
recently approved crizotinib as a TKI to ROS1
rearrangement of NSCLC, we consider that the patients
potentially harboring ROS1 rearrangement can be
recruited by preliminary screening, therefore, more
patients can receive TKI therapy, and the correlation
between fusion types and TKI response or histopath-
ology can be analyzed.
There are some limitations in our study. First of all,
the qRT-PCR analysis was performed in only 159 cases.
In order to analyze the concordance between qRT-PCR
and FISH, all the recruited cases should be tested by
qRT-PCR. However, some of the biopsied cases had in-
sufficient amount of tissue to perform the qRT-PCR.
Moreover, in order to clarify the relationship between
fusion partners and TKIs response, and the correlation
between fusion types and histopathology, more positive
Table 3 H-score, intensity and extent of IHC
IHC FISH+ FISH- Sensitivity Specificity
H-score
≥50 10 18 100 % 92.1 %
≥100 10 5 100 % 97.8 %
≥150 10 0 100 % 100.0 %
≥200 5 0 50.0 % 100.0 %
≥250 3 0 30.0 % 100.0 %
Intensity
1+ 10 32 100 % 85.7 %
2+ 10 1 100.0 % 99.6 %
3+ 3 0 30.0 % 100 %
Extent
≥10 % 10 29 100.0 % 87.28 %
≥20 % 10 25 100.0 % 89.04 %
≥30 % 10 20 100.0 % 91.23 %
≥40 % 10 15 100.0 % 93.42 %
≥50 % 10 14 100.0 % 93.86 %
≥60 % 10 9 100.0 % 96.05 %
≥70 % 9 9 90.0 % 96.05 %
≥80 % 7 4 70.0 % 98.25 %
≥90 % 4 1 40.0 % 99.56 %








IHC ROS1 2-3+ 10 1 < 0.01a 0.950
IHC ROS1-, 1+ 0 227
IHC extent≥ 60 % 10 9 < 0.01a 0.672
IHC extent < 60 % 0 219
IHC H-score≥ 150 10 0 < 0.01a 1.000
IHC H-score < 150 0 228
aFisher exact test
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Table 5 The details of follow-up studies
Case no. Surgery Histopathology Chemotherapy ROS1 detection CT imagine TKI start time Response Reexamination
CT imagine
Side effects
Patient 3 Video-assisted thoracic
surgery (VATS) of the







IHC, FISH and qRT-PCR




in his left thoracic
wall was
approximate in

























IHC, FISH and qRT-PCR





























– IHC and FISH had






























cases are needed. Finally, the relation between faint and
weak staining of ROS1 IHC and other gene aberrance
was not clear since not all faint and weak staining cases
underwent EGFR mutation and ALK rearrangement
detection. Future studies will include more patients
carrying ROS1 arrangements (i.e. young, female, non-
smokers with adenocarcinoma) to obtain more positive
cases for the analysis.
Conclusions
In conclusion, IHC can be a reliable and effective method
for ROS1 rearrangements preliminary screening in patients
with NSCLC thanks to the high sensitivity and specificity
of IHC using the D4D6 mAb, while cutoff should be set at
diffusely (≥60 % tumor cells) 2–3+ cytoplasmic reactivity
and an H-score ≥150. FISH and qRT-PCR can be used as
confirmation analysis. Young, female, and non-smoking
patients with adenocarcinoma and without other RTKs
aberrance should undergo tests for ROS1 rearrangement
because patients with these characteristics may carry
ROS1 rearrangement. TKI therapy with crizotinib is
effective in patients with ROS1 rearrangements at ad-
vanced stages.
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